Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898258222> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2898258222 endingPage "viii130" @default.
- W2898258222 startingPage "viii130" @default.
- W2898258222 abstract "Background: Anaplastic and atypical recurrent meningioma constitute a rare pathology with very few available effective systemic treatments. Methods: A comprehensive analysis of 31 patients with atypical (WHO II) or anaplastic meningiomas (WHO III) that were recurrent and refractory to radiotherapy was conducted in two reference centers of Colombia. Only patients who had received some systemic treatment (sunitinib, everolimus/octeotride and bevacizumab) and had a complete follow-up were included. Overall survival (OS), progression free survival and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRa and VEGFR2 and its expression was correlated with outcomes. Results: Twenty two patients (72%) were females with a median age of 55 years (SD ± 15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octeotride/everolimus, 11 received sunitinib and the remaining 6 other second line agents. Median OS was 37.3 months (95%CI 28.5-42.1) and the PFS during the treatment with everolimus/octeotride (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2-21.1) and 9.1 months (95%CI 6.8-16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence, a finding that was not significant (36.0 vs. 29.5 months; p = 0.349). When analyzing molecular markers, the positive PDGFRa and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusions: Sunitinib and ocreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRa expression are strongly associated with major survival endpoints. Legal entity responsible for the study: Foundation for Clinical and Applied Cancer Research – FICMAC Funding: Supported by the Foundation for Clinical and Applied Cancer Research - FICMAC (Bogotá Colombia) research grant 011-2017SD. Disclosure: All authors have declared no conflicts of interest." @default.
- W2898258222 created "2018-11-02" @default.
- W2898258222 creator A5012871927 @default.
- W2898258222 creator A5016094900 @default.
- W2898258222 creator A5017909567 @default.
- W2898258222 creator A5018201051 @default.
- W2898258222 creator A5023908330 @default.
- W2898258222 creator A5027190771 @default.
- W2898258222 creator A5034618792 @default.
- W2898258222 creator A5035063101 @default.
- W2898258222 creator A5038974897 @default.
- W2898258222 creator A5057499890 @default.
- W2898258222 creator A5068514203 @default.
- W2898258222 creator A5073629477 @default.
- W2898258222 creator A5076258520 @default.
- W2898258222 creator A5082876643 @default.
- W2898258222 creator A5090767613 @default.
- W2898258222 date "2018-10-01" @default.
- W2898258222 modified "2023-10-17" @default.
- W2898258222 title "Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between ocreotide in combination with everolimus compared to sunitinib" @default.
- W2898258222 doi "https://doi.org/10.1093/annonc/mdy273.388" @default.
- W2898258222 hasPublicationYear "2018" @default.
- W2898258222 type Work @default.
- W2898258222 sameAs 2898258222 @default.
- W2898258222 citedByCount "0" @default.
- W2898258222 crossrefType "journal-article" @default.
- W2898258222 hasAuthorship W2898258222A5012871927 @default.
- W2898258222 hasAuthorship W2898258222A5016094900 @default.
- W2898258222 hasAuthorship W2898258222A5017909567 @default.
- W2898258222 hasAuthorship W2898258222A5018201051 @default.
- W2898258222 hasAuthorship W2898258222A5023908330 @default.
- W2898258222 hasAuthorship W2898258222A5027190771 @default.
- W2898258222 hasAuthorship W2898258222A5034618792 @default.
- W2898258222 hasAuthorship W2898258222A5035063101 @default.
- W2898258222 hasAuthorship W2898258222A5038974897 @default.
- W2898258222 hasAuthorship W2898258222A5057499890 @default.
- W2898258222 hasAuthorship W2898258222A5068514203 @default.
- W2898258222 hasAuthorship W2898258222A5073629477 @default.
- W2898258222 hasAuthorship W2898258222A5076258520 @default.
- W2898258222 hasAuthorship W2898258222A5082876643 @default.
- W2898258222 hasAuthorship W2898258222A5090767613 @default.
- W2898258222 hasBestOaLocation W28982582221 @default.
- W2898258222 hasConcept C121332964 @default.
- W2898258222 hasConcept C121608353 @default.
- W2898258222 hasConcept C126322002 @default.
- W2898258222 hasConcept C141071460 @default.
- W2898258222 hasConcept C142424586 @default.
- W2898258222 hasConcept C143998085 @default.
- W2898258222 hasConcept C2776694085 @default.
- W2898258222 hasConcept C2777802072 @default.
- W2898258222 hasConcept C2779160599 @default.
- W2898258222 hasConcept C2779490328 @default.
- W2898258222 hasConcept C2779699572 @default.
- W2898258222 hasConcept C2780739268 @default.
- W2898258222 hasConcept C71924100 @default.
- W2898258222 hasConcept C87355193 @default.
- W2898258222 hasConcept C90924648 @default.
- W2898258222 hasConceptScore W2898258222C121332964 @default.
- W2898258222 hasConceptScore W2898258222C121608353 @default.
- W2898258222 hasConceptScore W2898258222C126322002 @default.
- W2898258222 hasConceptScore W2898258222C141071460 @default.
- W2898258222 hasConceptScore W2898258222C142424586 @default.
- W2898258222 hasConceptScore W2898258222C143998085 @default.
- W2898258222 hasConceptScore W2898258222C2776694085 @default.
- W2898258222 hasConceptScore W2898258222C2777802072 @default.
- W2898258222 hasConceptScore W2898258222C2779160599 @default.
- W2898258222 hasConceptScore W2898258222C2779490328 @default.
- W2898258222 hasConceptScore W2898258222C2779699572 @default.
- W2898258222 hasConceptScore W2898258222C2780739268 @default.
- W2898258222 hasConceptScore W2898258222C71924100 @default.
- W2898258222 hasConceptScore W2898258222C87355193 @default.
- W2898258222 hasConceptScore W2898258222C90924648 @default.
- W2898258222 hasLocation W28982582221 @default.
- W2898258222 hasOpenAccess W2898258222 @default.
- W2898258222 hasPrimaryLocation W28982582221 @default.
- W2898258222 hasRelatedWork W1995193840 @default.
- W2898258222 hasRelatedWork W1996985265 @default.
- W2898258222 hasRelatedWork W2013969274 @default.
- W2898258222 hasRelatedWork W2074338299 @default.
- W2898258222 hasRelatedWork W2081703574 @default.
- W2898258222 hasRelatedWork W2137381953 @default.
- W2898258222 hasRelatedWork W2154171266 @default.
- W2898258222 hasRelatedWork W2226660015 @default.
- W2898258222 hasRelatedWork W2298717328 @default.
- W2898258222 hasRelatedWork W3111355294 @default.
- W2898258222 hasVolume "29" @default.
- W2898258222 isParatext "false" @default.
- W2898258222 isRetracted "false" @default.
- W2898258222 magId "2898258222" @default.
- W2898258222 workType "article" @default.